NXTSTIM, INC

NXTSTIM manufactures EcoAI, an FDA-approved, AI-powered non-invasive neuromodulation device for pain management. The platform combines transcutaneous nerve and electromyographic stimulation with machine learning to deliver personalized, closed-loop pain relief. EcoAI integrates Remote Therapeutic Monitoring (RTM) capabilities that meet CMS requirements, enabling real-time tracking of device use, patient feedback, and therapy outcomes. The system includes a wireless, wearable device (described as Oreo-sized), a mobile application for patient self-management, and a clinical dashboard for provider oversight. Clinical data demonstrates 92% patient compliance, 85% daily engagement, 75% AI prediction accuracy for pain intensity, 52% of patients achieving ≥30% pain relief, and 2.5-point average pain reduction on validated scales across 3,000+ treated patients. The company provides in-house clinical support via licensed practical nurses (LPNs) and licensed vocational nurses (LVNs) for ongoing monitoring, patient education, and care coordination. NXTSTIM's ecosystem integrates prescription, device setup, home-based therapy adjustment, and remote provider monitoring without requiring in-clinic visits. The device includes consumable gel pads for skin contact and transcutaneous stimulation.